NeurogesX (Nasdaq: NGSX) 25% LOWER; today announced that the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to the U.S.
FDA did not recommend FDA approval of a new indication for Qutenza® (Capsaicin) 8% patch for the management of neuropathic pain (nerve pain) related to HIV associated peripheral neuropathy (HIV-PN).
Exide Technologies (NASDAQ: XIDE) 22% LOWER; reported Q3 EPS of $0.84, compared to $0.34 reported last year.